Get the Latest Investment Ideas Delivered Straight to Your Inbox. Subscribe

News Update


Healthcare Firm Partners on Genetic Testing for Cannabis, Medication Responses
News Update

Share on Stocktwits


The offering should facilitate a more individualized treatment plan for patients.

Premier Health Group Inc. (PHGI:CSE; PHGRF:OTCQB; 6PH:FSE) announced in a news release it partnered with Navigator Genomics to incorporate into Premier's Juno electronic medical records system and MyHealthAccess apppatient results from Navigator's pharmacogenomics testing.

The test, which requires a saliva swab, reveals information about a patient's genetic responses to, or ability to effectively use, medical cannabis and 416 of the most prescribed medications, recommending those that would work best. It also indicates possible drug-to-drug interactions, inhibitors and inducers.

"By offering to place Navigator Genomics' test results directly into our Juno EMR and app, we can ensure our patients are prescribed the best medication and avoid those that simply do not genetically work or are possibly harmful," Premier's CEO Dr. Essam Hamza said in the release.

The Navigator Genomics test is sold directly to consumers or their physician, and the company is offering Premier Health Group patients and physicians a 10% discount on the test kit price.

Once a patient's results become available, they will be uploaded to Premier's EMR system and app, for discussion between patient and physician. (Such a discussion can take place virtually using the app's telemedicine feature, for instance.)

Also on Premier's app, Navigator Genomics will provide educational material about medical cannabis use. It will include cannabis glossaries, webinars, videos whitepapers and a list of chronic medical conditions that qualify a patient for medical cannabis use.

"Your results can lead you to receiving 'personalized medicine' from your doctors and dispensaries who can then prescribe what will work best and the medications for you to avoid. Consumers can thus avoid 'trial and error' while saving significant time and money and improve their overall quality of life," Navigator Genomics' Founder and CEO Travis Parr said in the release.


1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees. As of the date of this article, an affiliate of Streetwise Reports has a consulting relationship with Premier Health Group Inc. Please click here for more information. Within the last six months, an affiliate of Streetwise Reports has disseminated information about the private placement of the following companies mentioned in this article: Premier Health Group Inc.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Premier Health Group Inc., a company mentioned in this article.

Want to read more about Life Sciences Tools & Diagnostics investment ideas?
Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe